The Management of Hemorrhage Lead by New Oral Anticoagulants Dabigatran and Rivaroxaban

Abstract

Abstract: In recent years, various kinds of new oral anticoagulants(NOAC) have been put in use in clinic. One of the most representative drugs is a direct factor Xa inhibitor rivaroxaban and direct thrombin inhibitor dabigatran. Due to the short half-life of them, appropriate therapies include symptomatic supporting treatment and observation, which are likely to be effective for the majority of patients. In the case of life-threatening hemorrhage, clotting-factor substitutes may be appropriate in certain situations.

Key words: thrombus, hemorrhage, anticoagulant, rivaroxaban, dabigatran

CLC Number:

R973.2

WEN Li, HAN Xing, ZHOU Hao, ZHANG Xin-chao. The Management of Hemorrhage Lead by New Oral Anticoagulants Dabigatran and Rivaroxaban[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 15-18.

References

[1] Vigué B.Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage from theory to practice[J].Crit Care,2009,13(2):209.
[2] Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update[J].J Thromb Thrombolysis, 2011,31(3):326-343.
[3] Zikria J, Ansell J. Oral anticoagulation with Factor Xa and thrombin inhibitors: is there an alternative to warfarin[J]. Discov Med, 2009,8(43):196-203.
[4] Mittal M K, Rabinstein A A. Anticoagulation?related intracranial hemorrhages[J]. Curr Atheroscler Rep, 2012,14(4):351-359.
[5] Prasad S, Wootten M R, Kulinski N, et al. What to do when warfarin therapy goes too far[J]. J Fam Pract, 2009, 58(7):346-352.
[6] Janssen Pharmaceuticals, Inc.Xarelto(rivaroxaban) prescribing information[S]. Titusville,NJ:2013:2-3.
[7] Johnson & Johnson Pharmaceutical Research & Development. Rivaroxaban for the prevention of stroke and non-central nervous system(CNS) systemic embolism in patients with atrial fibrillation[R]. Advisory committee briefing document, 2011:30-32.
[8] Turpie A G, Lassen M R, Davidson B L, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial[J].Lancet, 2009,373(9676): 1673-1680.
[9] Patel M R, Mahaffey K W, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,8(365): 883-891.
[10] Boehringer Ingelheim Pharma GmbH & Co. Pradaxa(dabigatran etexilate capsules) [package insert][S]. Germany:Ingelheim,2012:3-4.
[11] Bershad E M, Suarez J I. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage:a review of the literature[J]. Neurocrit Care,2010,12(3):403-413.
[12] Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity[J]. Thromb Haemost, 2010,103(6):1116-1127.
[13] Hall A B, Carson B C. Reversal of warfarin-induced coagulopathy: review of treatment options[J]. J Emerg Nurs,2012,38(1):98-101.
[14] Gruber A, Marzec U M, Buetehorn U, et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates[J]. Blood,2008,112(8):3825.
[15] Perzborn E, Harwardt M. Recombinant factor VIIA partially reverses the effects of the factor XA inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro[J]. J Thromb Haemost, 2007,5(suppl 2): Abstract P-W-640.
[16] Eerenberg E S, Kamphuisen P W, Sijpkens M K, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects[J]. Circulation, 2011,124(14):1573-1579.
[17] Eerenberg E S, Sijpkens M K, Kamphuisen P W, et al. Prothrombin complex concentrate reverses the anticoagulant effect of rivaroxaban in healthy volunteers[J]. Blood,2010,116(6):Abstract 1094.
[18] Patel M R, Maha ffey K W, G ar g J, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10):883-891.
[19] Guyatt G H, Norris S L, Schulman S, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 suppl):e89S-e119S.
[20] Cairns J A, Connolly S, McMurtry S, et al; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter[J]. Can J Cardiol, 2011,27(1):74-90.
[21] Bershad E M, Suarez J I. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature[J]. Neurocrit Care,2010,12(3):403-413.